For the quarter ending 2026-03-31, IONS has $3,449,969K in assets. $2,958,555K in debts. $173,381K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Cash and cash equivalents | 173,381 | 338,341 | 297,304 | |
| Short-term investments | 1,745,732 | 1,901,830 | 1,992,676 | |
| Escrow deposit for maturity of 0 percent convertible senior notes due april 2026 | 632,511 | - | - | |
| Contracts receivable | 73,684 | 24,608 | 52,580 | |
| Inventories | 5,557 | 10,470 | 8,481 | |
| Other current assets | 306,080 | 243,744 | 226,109 | |
| Total current assets | 2,936,945 | 2,518,993 | 2,577,150 | |
| Property, plant and equipment, net | 142,401 | 106,117 | 111,951 | |
| Right-of-use assets | 235,064 | 241,993 | 163,933 | |
| Deposits and other assets | 135,559 | 165,988 | 132,099 | |
| Total assets | 3,449,969 | 3,033,091 | 2,985,133 | |
| Accounts payable | 26,030 | 14,326 | 22,800 | |
| Accrued compensation | 36,049 | 57,019 | 46,564 | |
| Accrued liabilities | 126,549 | 99,310 | 98,957 | |
| Income taxes payable | 2,874 | 101 | 81 | |
| 0 percent convertible senior notes due april 2026 | 432,500 | 630,911 | 630,118 | |
| Current portion of deferred contract revenue | 69,199 | 76,986 | 75,910 | |
| Convertible senior notes, net-Convertible Senior Notes175Percent | - | 567,123 | 566,420 | |
| Other current liabilities | 23,390 | 24,803 | 22,806 | |
| Convertible senior notes, net-Convertible Senior Notes0Percent | - | 0 | 0 | |
| Total current liabilities | 716,591 | 903,456 | 897,236 | |
| Long-term deferred contract revenue | 75,745 | 107,906 | 125,095 | |
| Convertible senior notes, net-Convertible Senior Notes Due2030 | 752,425 | - | - | |
| Convertible senior notes, net-Convertible Senior Notes Due2028 | 568,540 | - | - | |
| Liability related to sale of future royalties, net | 557,765 | 545,182 | 541,205 | |
| Long-term lease liabilities | 259,215 | 262,672 | 164,379 | |
| Long-term obligations | 28,274 | 28,785 | 59,074 | |
| Total liabilities | 2,958,555 | 2,415,124 | 2,353,409 | |
| Common stock, 0.001 par value 300,000,000 shares authorized, 165,902,064 and 163,304,875 shares issued and outstanding at march 31, 2026 and december 31, 2025, respectively | 166 | 161 | 159 | |
| Additional paid-in capital | 3,245,994 | 3,045,585 | 2,932,747 | |
| Accumulated other comprehensive loss | -31,023 | -25,978 | -27,987 | |
| Accumulated deficit | -2,723,723 | -2,401,801 | -2,273,195 | |
| Total stockholders' equity | 491,414 | 617,967 | 631,724 | |
| Total liabilities and stockholders equity | 3,449,969 | 3,033,091 | 2,985,133 | |
IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS)